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Abstract
Background
Amulticenter study was conducted to evaluate the diagnostic performance and the time to
identifcation of the Verigene Blood Culture Test, the BC-GP and BC-GN assays, to identify
both Gram-positive and Gram-negative bacteria and their drug resistance determinants
directly from positive blood cultures collected in Hong Kong.
Methods and Results
A total of 364 blood cultures were prospectively collected from four public hospitals, in
which 114 and 250 cultures yielded Gram-positive and Gram-negative bacteria, and were
tested with the BC-GP and BC-GN assay respectively. The overall identification agreement
for Gram-positive and Gram-negative bacteria were 89.6% and 90.5% in monomicrobial
cultures and 62.5% and 53.6% in polymicrobial cultures, respectively. The sensitivities for
most genus/species achieved at least 80% except Enterococcus spp. (60%), K.oxytoca
(0%), K.pneumoniae (69.2%), whereas the specificities for all targets ranged from 98.9% to
100%. Of note, 50% (7/14) cultures containing K.pneumoniae that were missed by the BC-
GN assay were subsequently identified as K.variicola. Approximately 5.5% (20/364) cul-
tures contained non-target organisms, of which Aeromonas spp. accounted for 25% and
are of particular concern. For drug resistance determination, the Verigene test showed
100% sensitivity for identification of MRSA, VRE and carbapenem resistant Acinetobacter,
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and 84.4% for ESBL-producing Enterobacteriaceae based on the positive detection of
mecA, vanA, blaOXA and blaCTXM respectively.
Conclusion
Overall, the Verigene test provided acceptable accuracy for identification of bacteria and
resistance markers with a range of turnaround time 40.5 to 99.2 h faster than conventional
methods in our region.
Introduction
Sepsis is the ninth leading cause of mortality in Hong Kong, accounting for nearly 900 deaths
in 2014 [1]. It is initially caused by bloodstream infections (BSI) with pathogenic bacteria, due
to Enterobacteriaceaemembers and Staphylococcus spp. being the predominant etiological
agents [2, 3]. The mortality rate was shown to be highly associated with time to effective anti-
microbial treatment [3]. The risk of death increased by 6% to 10% for every hour of delay in
administration of effective antibiotics [4].
The conventional laboratory diagnosis for BSI relies on broth-based cultures of patients’
blood samples using automated, real-time monitoring blood culture systems. Upon broth posi-
tivity, direct Gram stain is performed and a portion of the broth culture is sub-cultivated onto
solid media to obtain isolated colonies. The subculture takes 18 to 48-hour incubation prior to
biochemical tests for a definitive bacterial identification. With the advent of Matrix-assisted
laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), the time to
identification for blood cultures can be shortened to around 5-hour [5–7]. However, conven-
tional drug susceptibility test is still required to determine the final antimicrobial susceptibility
pattern, which normally requires an additional 12–24 hours [8]. The time interval between
broth-culture positivity and the availability of final laboratory results leaves the clinicians with
limited information to enable clinical decisions during the critical phase of infection. Empiric
treatments with broad spectrum antimicrobials are always prescribed to BSI patients in
advance of culture and susceptibility results [9]. However in an era of increasing antibiotic
resistance, empirical antimicrobial agents may result in suboptimal therapy. In Hong Kong,
about 30% of E.coli isolated from blood culture were positive for extended-spectrum beta-lacta-
mase (ESBL) and more than 50% of patients infected with these resistant strains were actually
prescribed with inappropriate empirical treatment [9, 10]. A higher 28-day mortality rate was
shown to be significantly associated with ineffective empiric antimicrobial therapies [11].
Beyond its impact on mortality, ineffective treatment is also associated with longer hospital
stays [12], which present a significant financial challenge to the health care facility given that
hospitalization accounts for more than 80% of the total medical cost used for BSI cases [13].
Rapid microbiological methods that can shorten the turnaround time for bacterial identifica-
tion and antimicrobial susceptibility tests will definitely facilitate early clinical management,
thus reducing the mortality and relieving the corresponding financial burden.
The Verigene Blood Culture Test (Nanosphere, Northbrook, IL) is a closed, fully automated,
microarray-based platform that is designed not only for bacterial identification but also drug
resistance detection directly from positive blood culture broths within 2.5 hours. The platform
consists of two assay panels: the BC-GP assay and the BC-GN assay. The BC-GP assay obtained
CE-IVD mark for detection of Gram positive organisms commonly isolated from blood cul-
tures including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis,
Staphylococcus spp.,Micrococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes,
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Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus spp., Enterococcus faeca-
lis, Enterococcus faecium and Listeria spp. In addition, the assay also detects the presence of the
mecA gene in S. aureus and S. epidermidis and vanA and vanB genes in E. faecalis and E. faecium.
The BC-GN assay is also a CE-IVD assay designed for the detection of Gram negative bacteria
that are frequently associated with sepsis, which includes Acinetobacter spp., Citrobacter spp.,
Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus spp., Pseudo-
monas aeruginosa and Serratia marcescens, as well as the drug resistance genes encoding for
β-lactamases and carbapenemases–blaCTX-M, blaIMP, blaVIM, blaKPC, blaNDM, and blaOXA.
Evaluation studies for the Verigene test have been extensively conducted in the U.S. and
Europe to assess the diagnostic performance. The sensitivity and specificity of the assay for bac-
terial identification ranged from 92.6%–98.6% and 95.4%–99.5% respectively. The concordant
rate of resistance detection ranged from 88.9% to 100% as compared to phenotypic susceptibil-
ity tests [14–20].
However, it should be noted that the performance reported in Western countries might not
be reproducible in Hong Kong given that the bacterial lineages and drug resistance patterns fre-
quently encountered in our region are not congruent with the spectra circulating in the U.S.
and Europe. This can be exemplified by the observation that Gram positive bacteria accounted
for 52% to 77% of bacterial sepsis in the U.S. whereas Gram negative bacilli, particularly E.coli,
represented causative agents for about 60% of BSI cases in Hong Kong [21–23]. Therefore,
regional evaluation is necessary to determine the applicability of the assay in our hospitals.
In this study, we investigated the diagnostic accuracy (sensitivity and specificity) of the Veri-
gene BC-GP ad BC-GN assays to identify bacteria and their resistance determinants directly
from positive blood culture broths collected from four public hospitals serving different district
areas in Hong Kong. A retrospective comparison of time to identification between the Verigene
Blood Culture Test and conventional culture-based methods was also conducted at one of the
study sites.
Materials and Methods
Collection of Blood Culture Broths
A total of 364 positive blood culture broths from non-duplicated patients with suspected sepsis
were collected from January 2014 to May 2014 at four public acute hospitals located at different
district areas across Hong Kong, namely 1,633 bed Pamela Youde Nethersole Eastern Hospital
(PYNEH), 1,753 bed Princess Margaret Hospital (PMH), 1,403 bed United Christian Hospital
(UCH) and 1,702 bed Queen Mary Hospital (QMH). Bactec plus/F (Becton Dickson, US) aero-
bic culture bottles were used in all the study sites except for PMH where the BacT/Alert FA
(bioMerieux, France) system was used. The bottles were incubated in the corresponding auto-
mated blood culture system until positive within five days. Upon broth positivity, samples
from PYNEH, PMH and UCH were sent to The Hong Kong Polytechnic University for the
Verigene Blood Culture Test within 24 hours. If the samples could not be run within 24 hours,
they were stored at 4°C for up to 48 hours. For QMH, after flagging positive by the blood cul-
ture system, the samples were almost processed immediately with BC-GP or BC-GN tests
using another Verigene system established in their laboratory.
Conventional Culture-Based Methods for Bacterial Identification and
Drug Susceptibility Test
Positive blood culture broths were inoculated onto Columbia blood agar, chocolate agar and
MacConkey agar for overnight incubation at 37°C in the presence of 5% CO2. The isolated
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colony(s) were identified by automated biochemical platform, Vitek 2 (bioMérieux). Kirby-
Bauer disk diffusion method were performed and interpreted according to CLSI guideline
(M100-S21) to determine the drug susceptibilities [8]. Further tests were done to confirm the
presence of methicillin resistant S. aureus (MRSA), vancomycin resistant Enterococci (VRE),
ESBL-producing Enterobacteriaceae and carbapenem resistant Enterobacteriaceae (CRE) [8].
MRSA was confirmed by resistance to cefoxitin disk and positive growth of S. aureus colonies
(mauve in colour) on the ChromID MRSA agar (bioMérieux) whereas VRE was primarily
detected by brain heart infusion agar supplemented with 6μg/mL vancomycin, followed by
confirmation with E-test (bioMérieux). Combined disk method (CDM) using ceftazidime with
and without clavulanic acid was used as a confirmatory test for ESBL in E.coli, Klebsiella spp.,
and Proteus spp. For Enterobacter spp., Citrobacter spp. and Serratia marcescens, cefepime disk
and cefepime-clavulanic acid disk were used for detection of ESBL [24]. For CRE determina-
tion, Enterobacteriaceae with zone diameter<23mm for imipenem were subjected to com-
bined disk methods using ertapenem, meropenem and imipenem disks placed adjacent to
aminophenyl boronic acid (APBA) and ethylenediaminetetraacetic acid (EDTA) as the pheno-
typic confirmatory test. To avoid bias, technologists conducting the conventional tests were
blinded to the results obtained using the Verigene test.
Verigene BC-GP and BC-GN Assay
Based on the primary Gram stain results, cultures with Gram positive organisms were subjected
to the Verigene BC-GP assay whereas cultures containing Gram negative organisms were tested
with the Verigene BC-GN assay. All the procedures were carried out according to manufacturer’s
instructions. In brief, a total of 350μl and 700μl of positive blood cultures were loaded into the
corresponding extraction trays of the BC-GP assay and the BC-GN assay respectively. The
extraction trays were then transferred to the processor SP along with other consumables and the
test cartridge containing the microarray slides. The instrument automatically performed nucleic
acid extraction, purification, microarray hybridization and signal amplification. The whole pro-
cess took 2.35 hours for the BC-GP assay or 1.88 hour for the BC-GN assay. Upon completion,
the test cartridge was removed from processor SP. The microarray slide was manually inserted
into Verigene Reader for analysis. The light source of the Verigene Reader excited the signal-
enhanced nanoparticles that were specifically bound to the bacteria-specific or resistance-gene-
specific probes captured on the slide. The relative brightness of each spot were measured by the
photosensor. Positive and negative results were reported as “Detected” or “Not detected” for each
bacteria and resistance determinants featured by the Verigene test respectively. “No Call” flag
was given to the samples with indeterminate results. These samples were repeated a single time.
The repeated result was considered as the final result for the sample.
Discrepant Analysis for Bacterial Identification and Drug Resistance
Regarding the bacterial identification, isolates generating discrepancies between the conven-
tional culture-based method and the Verigene test were analyzed by 16s ribosomal RNA
(rRNA) sequencing according to previous studies [25, 26]. The sequence similarity was deter-
mined using the EzTaxon server (http://eztaxon-e.ezbiocloud.net/ezt_identify). yggE gene
sequencing was performed to differentiate K. variicola from K. pneumoniae [27].
In case of discrepancies between genotypic drug resistance results inferred by the Verigene
test and phenotypic susceptibility test results, PCR-based assays were performed to confirm the
presence of resistance genes.
For discordance in methicillin resistance in the specimens with S. aureus and S. epidermidis,
our in-house real time polymerase chain reaction (PCR) assay were used to detect the presence
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ofmecA gene [28]. In case of contradictory VRE results, the presence of vanA and vanB genes
was verified by vanA- and vanB-specific PCR assays according to the protocol described by
Bell et al [29]. For the mismatches in susceptibilities to β-lactam drugs in Gram negative organ-
isms, the presence of resistance genes associated with β-lactamases, such as blaTEM, blaSHV,
blaCTXM, blaOXA, blaKPC and blaNDM were firstly identified by multiplex PCR assays [30, 31] fol-
lowed by genotyping using bi-directional Sanger sequencing.
Assessment of Time to Identification Using the Verigene Test and
Conventional Culture-Based Methods
A retrospective comparison of turnaround time for bacterial identification was conducted
using a total of 125 positive blood cultures collected from QMH, in which 38 cultures were pos-
itive for Gram positive organisms whereas 87 cultures contained Gram negative organisms.
These cultures were a subset of the 364 cultures collected for evaluation of the diagnostic per-
formance of the Verigene test and all of them were positive for the organisms featured by the
Verigene panel. Unlike the other three study sites, QMH had three Verigene systems estab-
lished in their clinical microbiology laboratory, which allowed more accurate comparison of
time to result between the Verigene test and routine culture-based methods. The time at which
the primary Gram stain result was reported was considered as time-zero for turnaround time
determination. For the Verigene test, the time elapsed between time-zero and the completion
time of the BC-GP assay and the BC-GN assay recorded in the Verigene system was considered
as the time to result. For the conventional culture-based method, the time at which final results
were input into the laboratory information system by technologists was used to determine the
total time required for bacterial identification.
Data Processing and Statistical Analysis
The diagnostic sensitivity and specificity of the Verigene BC-GP and BC-GN assays for bacterial
identification and drug resistance determination were calculated using standard methods.
Ninety-five percent confident intervals (95% CI) were calculated using the adjustedWald method
by free software available from http://www.measuringusability.com/wald.htm. Pair t-test or Wil-
coxon signed rank test where appropriate was used to determine the statistically significant differ-
ence in time to result between the Verigene tests and the routine conventional methods.
Ethical Considerations
The study protocol was carefully reviewed and approved by the Human Subjects Ethics Sub-
committee under the University Research Committee of The Hong Kong Polytechnic Univer-
sity. Individual informed consent was waived by the ethics committee because this study used
currently existing samples collected during the course of routine medical care and did not pose
any additional risks to the patients.
The Verigene Blood Culture Test are not currently approved for standard clinical procedure
by Hospital Authority in Hong Kong and not ethically permitted for clinical diagnosis. Thus,
we did not inform the clinicians of the results obtained from the methods.
Results
Overall Concordance
Among the 364 blood culture samples collected in the study, 78,8% (287/364) and 94.2% (343/
364) were flagged positive in the blood culture system within 24-hour and 48-hour incubation
respectively. Overall, 31.3% (n = 114) and 68.7% (n = 250) were found to contain Gram
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positive and Gram negative bacteria respectively on the primary Gram stain. A total of 16 cul-
tures (11 Gram Positive and 5 Gram negative) generated an indeterminate result in the initial
analysis, giving the initial call rate of 95.6%. Of these, two were resolved following a single retest
for a final call rate of 96.2% (350/364). In this study, only 5.5% (20/364) cultures contained
organisms not included on the Verigene test panel. Among 364 blood cultures, 90.1% (n = 328)
were monomicrobial, and 9.9% (n = 36) contained at least two bacteria. The overall concor-
dance rate in bacterial identification between the Verigene test and reference culture method
was 86.8% (BC-GP: 87.7%; BC-GN: 86.4%). Higher concordance was obtained in monomicro-
bial cultures (90.2%) than in polymicrobial cultures, of which only 55.6% (20/36) showed fully
concordant identification. The performances of the Verigene test in each study site are pre-
sented in Table 1. Of all the collected blood cultures, 94.0% (342/364) were tested with the Ver-
igene test within 24 hour after flagging positive by the blood culture system as suggested by the
manufacturer. For the 22 samples that were not analyzed within this period, they were stored
at 4°C up to 48 hours. The Verigene test results obtained for these samples (BC-GP: n = 4;
BC-GN: n = 18) were all concordant with reference culture method, indicating that the period
of specimen storage prior to the Verigene test did not affect the test results in this study.
Bacterial Identification for Gram Positive Organisms
From 114 blood cultures containing Gram positive organisms, a total of 121 isolates were
obtained (Table 2). The majority of these belonged to Staphylococcus spp, which accounted for
60.3% (73/121) of all Gram positive organisms isolated in this study, followed by Streptococcus
spp., 22.3% (27/121), Enterococcus spp., 9.9% (12/121), and Listeria spp., 0.8% (1/121). A total
of 8 isolates were a genus/species not included in BC-GP panel, including Bacillus spp. (n = 3),
Kocuria spp. (n = 3), Corynebacterium spp. (n = 1) and Candida krusei (n = 1) (Table 2).
Among 73 cultures containing Staphylococcus spp., four monomicrobial cultures, including
one harbouring S. aureus and three containing S. haemolyticus, were reported as “No Call” in
spite of single retest (Table 3). For those which had valid verigene results, Staphylococcus spp.
were identified with 100% (69/69) sensitivity and 100% (48/48) specificity. S. aureus repre-
sented the most predominant species of Gram positive organisms isolated in this study, with
sensitivity and specificity of 100%. BC-GP test also identified all S. epidermidis isolates (n = 4)
with no false positivity (Table 2). Other CoNS isolated in this study included S. hominis
(n = 8), S. caprae (n = 4), S. intermedius (n = 3), and S. jettensis (n = 3). All of them were cor-
rectly reported as Staphylococcus spp. in the BC-GP test.
For Streptococcus spp., all the species-level targets, namely S. pyogenes (n = 2), S. agalactiae
(n = 3), S. anginosus group (n = 1) and S. pneumoniae (n = 7) yielded 100% sensitivity. A total
of 14 Streptococcus spp. not included in the BC-GP panel were isolated, including S.mitis
(n = 6), S. dysgalactiae (n = 3), S. bovis (n = 3), S. gallolyticus (n = 1) and S. sanguinis (n = 1).
All were identified as Streptococcus spp. by BC-GP test except two (one S.mitismonomicrobial
culture and one S. gallolyticusmonomicrobial culture) were reported as “No Call” (Table 3).
With the exception of one monomicrobial culture of Kocuria spp. falsely identified as S. pneu-
moniae, all the species-level targets for Streptococci yield 100% specificity (Table 2).
Compared with Staphylococcus spp. and Streptococcus spp., the accuracy of the BC-GP for
Enterococcus spp. was much lower. The sensitivities for E. faecalis and E. faecium achieved only
66.7% (4/6) and 50% (2/4) respectively (Table 2). Four cultures (two E. faecalis and two E. fae-
cium) had results of “Not Detected”, and thus were considered as false negative cases. Addi-
tionally, invalid results (No Call) were obtained for two monomicrobial cultures containing E.
faecalis and E. faecium respectively (Table 3). Only one blood culture harbouring L.monocyto-
genes was obtained in this study. The BC-GP was 100% sensitive and specific for the
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identification of this organism. For the eight nontarget organisms, 50% of them were correctly
assigned as “Not Detected” in the BC-GP Test. One monomicrobial culture with Bacillus spp.
and one mixed culture of two Kocuria spp. isolates yielded invalid results, and one Kocuria
rosea isolate was misidentified as S. pneumoniae in the BC-GP test.
Bacterial Identification for Gram Negative Organisms
A total of 279 Gram negative bacteria were isolated, in which E. coli was the most frequently
isolated species, accounting for 59.1% (165/279) of Gram negative bacteria and 41.3% (165/
400) of total bacteria isolated in this study. K. pneumonia ranked the second, 18.6% (52/279),
followed by P. aeruginosa, 6.1% (17/279), Proteus spp., 3.6% (10/279), Enterobacter spp., 3.6%
(10/279), Acinetobacter spp., 1.4% (4/279), K. oxytoca, 1.1% (3/279), Citrobacter spp., 0.4% (1/
279), and Serratia marcescens, 0.4% (1/279) (Table 4).
The sensitivities of the BC-GN test for each genus/species were as follow: Acinetobacter spp.,
Citrobacter spp., Enterobacter spp., Proteus spp. and Serratia marcescens: 100%; E.coli: 95.8%; P.
aeruginosa: 81.3%; K. pneumoniae: 69.2%; and K. oxytoca: 0% (Table 4).
Of the 26 isolates with false negative results by the BC-GN test, 53.8% (14/26) were identi-
fied as K. pneumoniae by Vitek 2. However, 16s rRNA sequencing of these isolates revealed
Table 2. Performance of BC-GP for identification of Gram positive organisms.
No. (%) of isolates
Organisms Total Correctly
identiﬁed
Not
detected
Misidentiﬁed No
Call
Sensitivity
(%)
95% CIa Speciﬁcity
(%)
95% CIa
Staphylococcus
spp.
73
(60.3)
69 (94.5) - - 4 100 95.5–100 100 93.6–100
S. aureus 48
(39.7)
47 (97.9) - - 1 100 93.5–100 100 95.7–100
S. epidermidis 4 (3.3) 4 (100) - - - 100 54.3–100 100 97.3–100
Streptococcus spp. 27
(22.3)
25 (92.6) - - 2 100 88.4–100 98.9 92.1–
99.9
S. pyogenes 2 (1.7) 2 (100) - - - 100 36.9–100 100 97.3–100
S. agalactiae 3 (2.5) 3 (100) - - - 100 47.0–100 100 97.3–100
S. anginosus gr. 1 (0.8) 1 (100) - - - 100 22.4–100 100 97.4–100
S. pneumoniae 7 (5.8) 7 (100) - - - 100 67.8–100 99.1 94.7–
99.9
E. faecalis 7 (5.8) 4 (57.1) 2 (28.6) - 1 66.7 29.6–
90.8
100 97.2–100
E. faecium 5 (4.1) 2 (40) 2 (40) - 1 50 15.0–
85.0
100 97.3–100
Listeria 1 (0.8) 1 (100) - - - 100 22.4–100 100 97.4–100
Nontarget 8 (6.6) - 4 (50) 1 3
Bacillus spp. 3 - 2 - 1
Candida krusei 1 - 1 - -
Diphtheroids 1 - 1 - -
Kocuria spp. 3 - - 1b 2
Total 121 101 8 1 11
a95% conﬁdence interval was calculated using Adjusted Wald Method (http://www.measuringu.com/wald.htm)
b Misidentifed as S. pneumoniae
doi:10.1371/journal.pone.0139728.t002
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that 50% (7/14) of them indeed shared 100% similarity to Klebsiella variicola (Table 3). As con-
firmed by yggE gene sequencing, K. variicola was considered as the final identification for these
seven monomicrobial cultures, and sensitivity for K. pneumoniae was raised to 80% (36/45)
after the discrepancy resolution. Among the 6 isolates reported as E. coli by both Vitek 2 and
16s rRNA sequencing but not detected by the BC-GN assay, two were obtained from monomi-
crobial cultures and four were isolated from polymicrobial bacteremia cases including one
bimicrobial culture with E. coli and P. aeruginosa, one bimicrobial with E.coli and P.mirabilis,
and one tetramicrobial culture containing K. pneumoniae, P.mirabilis and two E. coli strains
(Table 3). In addition, the BC-GN assay reported false negative results for three cultures con-
taining P. aeruginosa, including two monomicrobial cultures and one mixed culture with E.
coli. The 16s rRNA sequences of these three isolates showed 100% similarity to P. aeruginosa.
Surprisingly, the BC-GN assay failed to detect all the three monomicrobial culture of K. oxytoca
as confirmed by Vitek 2 and 16s rRNA sequencing.
Table 3. The identities of bacteria in cultures with discordant results reported by culture-basedmethod and the Verigene Test.
Culture results No. of
culture
Verigene Test results 16s Sequencing (Sequence similarity %)
Monomicrobial Culture
S. aureus 1 No Call S. aureus subsp. aureus (100%)
CNS 3 No Call S. haemolyticus (99.7%)
S. viridans 1 No Call S. mitis (99.27%)
S.gallolyticus 1 No Call S. gallolyticus subsp. pasteurianus (100%)
E. faecalis 1 No Call E. faecalis (100%)
E. faecium 2 Not Detected E. faecium (100%)
E. faecium 1 No Call E. faecium (100%)
Kocuria spp.a 1 S. pneumoniae Kocuria koreensis (97.28%)
E. coli 2 Not Detected E. coli (100%)
K. pneumoniae 1 Not Detected K. pneumoniae subsp. pneumoniae (99.83%)
K. pneumoniae 7 Not Detected K. variicola (100%)
K. pneumoniae 1 K. pneumoniae / K. oxytoca K. pneumoniae subsp. ozaenae (100%)
K. pneumoniae 1 K. pneumoniae /
Enterobacter spp.
K. pneumoniae subsp. ozaenae (100%)
P. aeruginosa 2 Not Detected P. aeruginosa (100%)
K. oxytoca 3 Not Detected K. oxytoca(100%)
R. planticolaa 1 K. oxytoca R. planticola (100%)
Polymicrobial Culture
CNS / E. faecalis 1 Staph. Spp S. petrasii subsp. petrasii (100%) / E. faecalis (100%)
S. aureus / E. faecalis 1 S. aureus S. aureus subsp. aureus (100%) / E. faecalis (100%)
E. coli / P. aeruginosa 1 P. aeruginosa E. coli (100%) / P. aeruginosa (100%)
E. coli / P. aeruginosa 1 E.coli E. coli (100%) / P. aeruginosa (100%)
E. coli / Proteus 1 Proteus spp. E.coli (99.86%) / Proteus mirabilis (100%)
E. coli / K. pneumoniae 1 K. pneumoniae /
Enterobacter spp.
E. coli (100%) / K. pneumoniae subsp. pneumoniae (99.85%)
E. coli/ K. pneumoniae 6 E.coli E. coli (100%) / K. pneumoniae subsp. pneumoniae (99.85%)
P. mirabilis / M. morganiia 1 No Call P. mirabilis (100%) / M. morganii (100%)
E. coli / E.coli / P.mirabilis / K.
pneumoniae
1 Proteus spp. / K.
pneumoniae
E. coli (100%) / E. coli (100%) / P. mirabilis (100%) / K. pneumoniae
subsp. pneumoniae (99.83%)
a Organisms are not included in the Verigene Test identiﬁcation panel
doi:10.1371/journal.pone.0139728.t003
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All the targets featured by the BC-GN panel yielded 100% specificity except for Enterobacter
spp. (99.3%) and K. oxytoca (99.3%). One mixed culture of E. coli and K. pneumoniae was
wrongly reported as Enterobacter spp. and K. pneumoniae, whereas two monomicrobial cul-
tures of K. pneumoniaemisidentified as K. pneumoniae / K. oxytoca and K. pneumoniae /
Enterobacter spp. respectively (Tables 3 and 4).
Table 4. Performance of BC-GN for idenifcation of Gram negative organisms.
No. (%) of isolates
Organisms Total Correctly
identiﬁed
Not
detected
Misidentiﬁed No
Call
Sensitivity
(%)
95% CIa Speciﬁcity
(%)
95% CIa
E.coli 165
(59.1)
158 (95.8) 6 (3.6) 1c - 95.8 91.3–
98.1
100 97.2–
100
K. pneumoniae 52
(18.6)
36 (69.2) 14 (27)d 2e - 69.2d 55.7–
80.2
100 98.6–
100
P. aeruginosa 17 (6.1) 13 (76.5) 3 (17.6) - 1 81.3 56.2–
94.2
100 98.8–
100
Proteus spp. 10 (3.6) 9 (90) - - 1 100 73.1–
100
100 98.8–
100
Enterobacter spp. 10 (3.6) 8 (80) - - 2 100 70.7–
100
99.3 97.2–
99.9
Acinetobacter spp. 4 (1.4) 4 (100) - - - 100 54.3–
100
100 98.8–
100
K. oxytoca 3 (1.1) - 3 (100) - - 0 0.0–
53.0
99.3 97.2–
99.9
Citrobacter spp. 1 (0.4) 1 (100) - - - 100 22.4–
100
100 98.8–
100
Serratia marcescens 1 (0.4) 1 (100) - - - 100 22.4–
100
100 98.8–
100
Nontargetb 16 (5.7) - 14 (87.5) 1 1
Aeromonas veronii 5 - 5 - -
Morganella morganii 3 - 2 - 1
Salmonella spp. 2 - 2 - -
Alcaligenes faecalis 1 - 1 - -
Burkholderia pseudomallei 1 - 1 - -
Haemophilus inﬂuenzae 1 - 1 - -
Raoultella planticola 1 - - 1f -
Pseudomonas putida 1 - 1 - -
Stenotrophomonas
maltophilia
1 - 1 - -
Total 279 0 40 4 5
a95% conﬁdence interval was calculated using Adjusted Wald Method (http://www.measuringu.com/wald.htm)
b Species were conﬁrmed by 16s rRNA sequencing
c Misidentiﬁed as Enterobacter spp. by BC-GN
d Seven isolates were conﬁrmed to be K. variicola instead of K. pneumoniaeby 16s rRNA and yGGEsequencing. After the discrepancy resolution, the
sensitivity for K. pneumoniae was raised to 80% (36/45).
e One was misidentiﬁed as mixed culture of K. pneumoniae and K. oxytoca whereas the other one was misidentiﬁed as mixed cultured of K. pneumoniae
and Enterobacter
f Misidentiﬁed as K. oxytoca
doi:10.1371/journal.pone.0139728.t004
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A total of 16 Gram negative bacteria isolated in this study were not included in the BC-GN
panel, namely Aeromonas hydrophila (n = 5),Morganella morganii (n = 3), Salmonella spp.
(n = 2), Alcaligenes faecalis (n = 1), Burkholderia pseudomallei (n = 1), Haemophilus influenza
(n = 1), Raoultella planticola (n = 1), Pseudomonas putida (n = 1), and Stenotrophomonas mal-
tophilia (n = 1). Fourteen of them were corrected reported as “Not Detected” by the BC-GN
test. One monomicrobial culture of R. planticola was misidentified as K. oxytoca, whereas one
mixed culture containing P.mirabilis andM.morganii were given an invalid result (Table 3).
Identification of Drug Resistance Determinants
With the exception of one “No Call” result obtained for a monomicrobial culture containing
MRSA, the BC-GP assay correctly identified all (26/26) MRSA and (4/4) MRSE with no false
positivity when compared with culture-based methods (Table 5). Vancomycin resistance was
observed in only one E. faecium isolate out of 12 Enterococcus spp. recovered from positive
blood cultures as determined by vancomycin E-test method. The BC-GP assay accurately
reported a vanA positive result for this VRE isolate (Table 5).
As confirmed by the combined disk method, a total of 46 extended-spectrum β-lactamase
(ESBL) producing Gram negative bacteria were obtained, in which 97.8% (45/46) had valid
Verigene results. Of these, 84.4% (38/45) were positive for blaCTX-M in BC-GN test (Table 5).
In the seven ESBL producers that were missed by the BC-GN test, blaCTX-M gene were posi-
tively detected by multiplex PCR assay. These isolates includes E. coli (n = 3), Enterobacter
xiangfangensis (n = 2), K. pneumoniae (n = 1), and K. variicola (n = 1) harbouring blaCTX-M-14
or blaCTX-M-15 as well as other β-lactamase genes such as blaSHV and blaTEM genes (Table 6). To
evaluate the clinical impact of blaCTX-M gene detection by the BC-GN assay, we calculated the
positive predictive value (PPV) and negative predictive value (NPV) in predicting cefotaxime
resistance in Enterobacteriaceae when using disk diffusion test results as the gold standard
comparator. All 38 isolates positive for blaCTX-M gene in BC-GN test showed a cefotaxime resis-
tance phenotype. Among 175 Enterobacteriaceae detected by the BC-GN assay but negative for
blaCTX-M gene, 22 isolates were resistant to cefotaxime. Therefore, the PPV for cefotaxime resis-
tance phenotype in these species by the BC-GN assay was 100% (38/38), whereas the NPV was
87.4% (153/175). The resistance genes harboured by the cefotaxime resistant Enterobacteria-
ceae isolates were characterized and were presented in Table 6.
There were 5 isolates (3 Acinetobacter spp. and 2 P. aeruginosa) resistant to imipenem as
determined by the disk diffusion test (Table 5). All the three Acinetobacter spp. were Acineto-
bacter baumannii with multidrug resistance phenotype. The BC-GN assay correctly detected
the blaOXA gene for all these isolates, and multiplex PCR further confirmed that they harboured
blaOXA-23 and blaOXA-51 (Table 6). Unfortunately, no resistance gene was identified for the two
imipenem resistant P. aeruginosa by the BC-GN assay. Multiplex PCR only revealed blaMOX
gene in both isolates (Table 6). To evaluate the clinical impact of blaOXA gene detection, we cal-
culated the PPV and NPV in detection of carbapenem resistance among Acinetobacter spp.
(n = 4) and P. aeruginosa (n = 13). All the three isolates harbouring blaOXA gene showed carba-
penem resistant phenotype. Among the 14 isolates negative for blaOXA gene, two showed resis-
tant to carbapenem, giving the PPV and NPV for carbapenem resistance of 100% (3/3) and
85.7% (12/14), respectively.
Time to Identification
The difference in time to report final bacterial identification using the Verigene Test and con-
ventional culture-based method was investigated for 125 bacterial isolates (38 Gram positive
and 87 Gram negative organisms) (Table 7). Of these, 23 belonged to Staphylococcus genus.
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The BC-GP reported bacterial identification and drug susceptibility result for cultures contain-
ing MSSA (n = 7), CoNS (n = 8), and MRSA (n = 10) an average of 46.65 h, 54.84, and even
91.10 h earlier than conventional culture-based method respectively. Among 13 positive cul-
tures with Streptococcus spp., the final identification using culture methods were reported an
average of 61.51 h after availability of the BC-GP results. For Enterococci, BC-GP results were
available an average of 76.15 h before routine culture results. Importantly, this includes the
identification of VRE, which was reported by BC-GP assay 99.15 h before the availability of
final results using conventional culture and susceptibility testing.
The time required for identification for Gram negative organisms using the BC-GN assay
was 1.88 h, which allowed the laboratory to report Enterobacteriaceae (n = 79) an average of
44.1 h earlier when compared with conventional culture-based method. Results for cultures
containing other Gram negative organisms, including seven P. aeruginosa and one Acinetobac-
ter spp., were available an average of 50.63 h and 74.12 h respectively before final identifications
were reported using conventional methods (Table 7).
Discussion
The major advantage of the Verigene Blood Culture Test is the rapid turnaround time, which
allows same day analysis and reporting of bacterial identification and resistance determinants
from positive blood cultures, and therefore facilitates both selection of appropriate antimicro-
bial treatment and implementation of infection control measures. The diagnostic accuracy of
the assay has been shown to be promising in several studies conducted in other countries [14–
17, 19, 20, 32–35]. However, the performance of molecular assays, particularly those relying on
oligonucleotide probes to capture target organisms or resistance determinants, were subjected
to genetic variation among bacterial lineages circulating in different geographic regions. Our
previous study reported that a hybridization probe-based real time PCR assay designated for
Table 5. Performance of Verigene Test in detection of drug resistant organisms.
No. of isolates
Drug resistant Organisms Total Correctly Detected Not Detected No Call Sensitivity (%) 95% CIa Speciﬁcity (%) 95% CIa
Gram Positive
MRSA 27 26 0 1 100 88.8–100 100 96.6–100
MRSE 4 4 0 0 100 54.3–100 100 97.3–100
VRE 1 1 0 0 100 22.4–100 100 97.4–100
Gram Negative
Cefotaxime resistant
Enterobacteriaceae (including
ESBL producers)
61 38 22 1 63.3 50.7–74.4 100 98.5–100
ESBL producing
Enterobacteriaceae
46 38 7 1 84.4 70.9–92.6 100 98.6–100
MDR Acinetobacter 3 3 0 0 100 47.0–100 100 98.8–100
Carbapenem-resistant
Psuedomonas
2 0 2 0 0 0.0–63.1 100 98.8–100
Total 98 72 24 2 75.0 65.4–82.6 100 98.9–100
MRSA: Methicillin resistant Staphylococcus aureus; MRSE: Methicillin resistant Staphylococcus epidermidis; VRE: Vancomycin resistant Enterococcus;
ESBL: Extended spectrum beta-lactamase; MDR Acinetobacter: Multidrug resisant Acinetobacter
a 95% conﬁdence interval was calculated using Adjusted Wald Method (http://www.measuringu.com/wald.htm)
doi:10.1371/journal.pone.0139728.t005
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the detection of MRSA from nasal swabs, which demonstrated an overall sensitivity of 95.2%
in a multicenter evaluation performed in U.S. [36], failed to detect almost 50% of MRSA iso-
lates collected in Hong Kong [28]. Results indicated that the performance reported in one geo-
graphic area might not be reproducible in another, and local evaluation is necessary to reflect
the applicability of a diagnostic assay in a particular region.
Among 364 blood cultures collected in this study, only 20 (5.5%) contained organisms not
included in the Verigene test panel, illustrating that the capture probe targets of the Verigene
test encompass the majority of organisms associated with bacteraemia cases in Hong Kong.
However, when compared with other studies performed in the U.S., Europe and other Asian
countries [14–17, 20, 32–35], the agreement in bacterial identification between the Verigene
test and reference methods was relatively low in our study (86.8% vs 92.6% -98.6%) although
the final call rate achieved 96.2%.
Table 6. Resistance gene profile in Gram negative organisms collected in this study.
Verigene BC-GN result
Organisms Resistance Gene proﬁle No. of isolates Organisms Resistance target
Drug resistant Gram negative isolates detected by Verigene Test (n = 41)
MDR A. baumannii OXA-23, OXA-51 3 Acinetobacter spp. OXA
ESBL producing E. coli CTXM-14 20 E.coli CTXM
ESBL producing E. coli CTXM-14, TEM 5 E.coli CTXM
ESBL producing E.coli CTXM-14, TEM, CIT 2 E.coli CTXM
ESBL producing E.coli CTXM-15 1 E.coli CTXM
ESBL producing E. coli CTXM-27 4 E.coli CTXM
ESBL producing E.coli CTXM-65 2 E.coli CTXM
ESBL producing K. pneumoniae CTXM-14, TEM 2 K. pneumoniae CTXM
ESBL producing K.variicolaa CTXM-14 1 Not Detected CTXM
ESBL producing K.variicolaa CTXM-65 1 Not Detected CTXM
Drug resistant Gram negative isolates failed to be detected by Verigene Test (n = 25)
ESBL producing E. coli CTXM-14 1 E. coli Not Detected
ESBL producing E. coli CTXM-14, TEM 1 E. coli Not Detected
ESBL producing E. coli CTXM-14, SHV 1 E. coli Not Detected
ESBL producing E. coli CTXM-15, TEM 1 E. coli Not Detected
ESBL producing K. pneumoniae CTXM-15, TEM, SHV 1 K. pneumoniae Not Detected
ESBL producing K.variicolaa CTXM-14, DHA 1 Not Detected Not Detected
ESBL producing E. xiangfangensisa CTXM-14, TEM 1 Enterobacter spp. Not Detected
ESBL producing E. xiangfangensisa CTXM-15, TEM 1 No Call No Call
Cefotaxime resistant E. coli SHV 3 E. coli Not Detected
Cefotaxime resistant E. coli TEM 1 E. coli Not Detected
Cefotaxime resistant E. coli CIT 1 E. coli Not Detected
Cefotaxime resistant E. coli TEM, SHV 1 E. coli Not Detected
Cefotaxime resistant K. pneumoniae SHV 4 K. pneumoniae Not Detected
Cefotaxime resistant K. pneumoniae SHV, DHA 1 K. pneumoniae Not Detected
Cefotaxime resistant C. freundiia Not Detected 2 Citrobacter spp. Not Detected
Cefotaxime resistant S. marcescens Not Detected 1 S. marcescens Not Detected
Cefotaxime resistant M. morganiia DHA 1 Not Detected Not Detected
Carbapenem-resistant P. aeruginosa MOX 2 P. aeruginosa Not Detected
a species identiﬁed by 16s Sequencing
doi:10.1371/journal.pone.0139728.t006
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Additionally, as recognized as a limitation by the manufacturer in the CE-IVD version of
the Verigene test that cultures containing more than one organism are prone to have false neg-
ative results, only 55.6% of polymicrobial cultures showed fully concordant results although
93.8% of them had the correct identification for at least one organism. The higher incidence of
false negativity could be due to minor populations of the polymicrobial culture being present
in a quantity lower than the limit of detection of the Verigene test or signal interference among
multiple capture probes on the array slide. In this study, QMH showed the lowest overall agree-
ment between the Verigene test and culture-based method among the four study sites, which
was considered to be attributed to the relatively high proportion of polymicrobial cultures. Fur-
thermore, polymicrobial cultures accounted for almost 10% of all collected positive blood cul-
tures. The rate was relatively high in comparison to those observed in other recent evaluation
studies of the BC-GP and BC-GN assay [14, 17, 19, 27, 32, 34]. This might also contribute to
the low overall concordance obtained in present study.
With respect to Gram positive organisms, Staphylococcus spp. are the most frequently Gram
positive bacteria isolated from blood cultures in this study. With the exception of one S. aureus
culture reported as “No Call”, the BC-GP assay accurately detected all S. aureus and S. epider-
midis isolates with 100% specificity. Identification and discrimination of MRSA and MSSA
from other CoNS in positive blood culture shortly after broth positivity is of particular impor-
tance as it can greatly reduce health care cost, shorten time to appropriate antibiotic treatment,
and improve patient outcome [37].
Similarly, for Streptococcus spp., those important causative organisms in BSI (S. pyogenes, S.
agalactiae, S. anginosus Gp. and S. pneumoniae) were all correctly detected by the BC-GP
assay. No false positivity was obtained for all species targets of Streptococci except S. pneumo-
niae. Previous studies showed that the most common misidentification by the BC-GP assay
were attributed to S.mitis group incorrectly identified as S. pneumoniae due to high sequence
Table 7. Difference in time to result between conventional culture-basedmethod and the Verigene Test.
Δ Time to Resulta
Organisms No. of
Isolatesb
Average Time to
identiﬁcation by
Culture-Based Method (h)
Average Time
to Result by
Verigene Test (h)
Average (h) Range (h) p-value
Staphylococcus spp. 23 63.76 2.35 61.41 22.65–494.65 p<0.001
MSSA 7 49 2.35 46.65 22.65–79.65 p = 0.012
MRSA 10 93.45 2.35 91.1 23.65–494.65 p<0.001
CNS 8 57.19 2.35 54.84 29.65–97.65 p<0.001
Streptococcus spp. 13 63.86 2.35 61.51 22.65–128.15 p<0.001
S. pneumoniae 3 42.83 2.35 40.48 22.65–56.65 p = 0.017
β-haemolytic Strept. 4 71.62 2.35 69.27 33.65–128.15 p<0.001
Viridians Group 6 55.08 2.35 52.73 25.65–83.65 p<0.001
Enterococcus spp. 2 78.5 2.35 76.15 53.15–99.15 p<0.001
VSE 1 55.5 2.35 53.15 n/a n/a
VRE 1 101.5 2.35 99.15 n/a n/a
Enterobacteriaceae 79 45.98 1.88 44.1 18.12–104.12 P<0.001
P. aeruoginosa 7 52.51 1.88 50.63 28.62–94.62 p<0.001
Acinetobacter spp. 1 76 1.88 74.12 n/a n/a
a Difference in time between BC-GP or BC-GN result and ﬁnal culture-based identiﬁcation and drug susceptibility test results
b Only the isolates with concordant results from cultured-based method and the Verigene test were included for the time to result assessment.
doi:10.1371/journal.pone.0139728.t007
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similarity [14, 16, 19]. However, the five S.mitis groups isolated in this study were either cor-
rectly reported as “Streptococcus spp.” (n = 4) or given an invalid result “No Call” (n = 1).
Instead, the BC-GP assay misidentified one Kocuria koreensis isolate as S. pneumoniae in the
present study although the two species shared only 78% homology for 16s ribosomal RNA
sequence (Data not shown). It is unclear whether this represented the presence of non-viable S.
pneumoniae or contamination of this sample with S. pneumoniae nucleic acid.
In this study, all the false negative results reported by the BC-GP assay were attributed to
Enterococcus spp., which represented the third most commonly isolated Gram positive genus.
E. faecalis is more commonly isolated from blood cultures and is more susceptible to antibiotics
when compared with E. faecium. A previous study indicated that 9.6% E. faecium isolates were
resistant to vancomycin whereas vancomycin resistance was only found in 0.5% E. faecalis iso-
lates [38]. This underscores the importance of identifying and differentiating these two organ-
isms along with vanA and vanB gene detection in order to prescribe appropriate antimicrobial
treatment for the patients with enterococcal bacteraemia. Unfortunately, we detected only
66.7% E. faecalis and 50% E. faecium isolates in contrast to 92.3%-100% Enterococcus spp.
being correctly detected using the BC-GP assay in other studies [14–16, 19, 39]. Molecular epi-
demiological studies indicated that the major lineage of hospital-derived E. faceium isolates in
China belonged to ST78 whereas ST17 was found to be the predominant strain in healthcare
settings of the Western countries [40, 41]. We speculate that the lineage specific single nucleo-
tide polymorphism may affect the binding affinity between the capture probes on the array and
the target DNA from the organisms, and thus contribute to the false negative results, though
this hypothesis was not tested.
The overall concordance rate of the BC-GN assay for the nine bacteria being identified was
86.4%. Interestingly, only 40.6% (13/32) discrepancies were accounted by polymicrobial cul-
tures. The majority of mismatches indeed happened on the monomicrobial cultures. Blood cul-
tures containing K. pneumoniae contributed to the largest number of false negative results
(n = 14) reported by the BC-GN assay. Upon 16s rRNA and yggE gene sequencing, we found
that 87.5% (7/8) monomicrobial cultures identified as K. pneumoniae by Vitek 2 but not
detected by the BC-GN assay were actually K. variicola. The proportion was even higher than
those reported by previous studies where 5.6% to 13.9% of K. pneumoniae that were not
detected by the BC-GN assay were finally identified as K. variicola [27, 32, 35]. There have
been an increasing number of reports indicating that K. variicola accounts for almost 10%
Klebsiella spp. isolated obtained from clinical specimens and it has been associated with severe
infections in humans including fatal sepsis [42–44]. Although literature revealed that K. varii-
cola isolates were generally more susceptible to piperacillin and cephalosporins than K. pneu-
moniae [42], one ESBL (blaCTX-M-14) producing K. variicola isolate was obtained in this study.
Of the seven K. variicola isolates, 57.1% (4/7) were obtained from QMH, which resulted in
lower overall concordant rate when compared to the other three study sites. Given the clinical
significance, the manufacturer should consider to include specific capture probes for K. varii-
cola in the next generation of the assay. In addition to the discrepancy on K. pneumoniae,
monomicrobal cultures of three K. oxytoca, two E. coli and two P. aeruginosa also failed to be
detected by the BC-GN assay in spite of a single retest for each of these samples. The reason for
the false negativity was unclear although we assumed that it might be due to the lineage of the
bacteria not being recognized by capture probes or bacterial concentrations at the time of
blood culture positivity below the limit of detection of the BC-GN assay [45, 46].
On the other hand, false positive results were reported for three monomicrobial and one
polymicrobial culture. One blood culture broth tested positive as K. oxytoca by the BC-GN
assay was subsequently identified as R. planticola by Vitek 2 and 16s rRNA sequencing.
Because of the high phenotypic and genotypic similarity between these two organisms, the
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manufacturer listed the presence of Raoultella spp. in blood cultures as a potential risk of false
positivity due to the cross-reactivity of the K. oxytoca capture probe. For the rest of misidenti-
fied cases, cross-reactivity of the capture probes is also considered as the major cause although
the presence of non-viable organisms or nucleic acid contamination cannot be ruled out.
A total of 24 isolates that were not included in the Verigene test panel were obtained in this
study. Most, if not all, of the Gram positive nontarget organisms, such as Bacillus spp. and
Corynebacterium spp. are common normal skin flora and are generally considered as contami-
nants of blood cultures [47]. In contrast, most of the Gram negative nontarget organisms iso-
lated in this study are associated with serious life threatening diseases. In line with an
evaluation study of the BC-GN assay performed in Korea, Aeromonas spp. accounted for
almost 5% of Gram negative organisms isolated from positive blood cultures [35]. In addition
to being ubiquitous in aquatic environments, Aeromonas spp. can also cause various kinds of
fatal and invasive infections [48]. Increasing cases with Aeromonas associated bacteraemia
have been reported in healthcare settings in Asian countries [49]. Hence, we consider the exclu-
sion of Aeromonas species and some other frequently encountered Gram negative pathogens,
such asM.morganii, and Salmonella spp., from the panel as a potential pitfall of the use of the
BC-GN assay in Asia.
For detection of drug resistance genes in Gram positive organisms, the BC-GP assay is
highly accurate, with correct detection ofmecA gene and vanA in all MRSA and VRE isolates
respectively in this study. The negative percent agreement on drug resistance determination
between the BC-GP assay and phenotypic methods was 100%, suggesting that therapy de-esca-
lation to narrower antimicrobial agent based on the BC-GP assay result could proceed safely.
In respect to identification of drug resistant Gram negative organisms, a major advantage of
the Verigene test over other multiplex platforms, such as FilmArray, is that the BC-GN panel
encompasses 6 genetic markers associated with resistance to various classes of β-lactam antibi-
otics. This allows us to timely and accurately detect Gram negative bacteria producing ESBLs
and carbapenemases, which are of particular clinical concern as the therapeutic options for
treating infections with these organisms are limited [50]. Nowadays, the vast majority of ESBLs
belong to the CTX-M type enzyme. In this study, all of ESBL producers harboured blaCTXM.
However, the BC-GN assay only identified 84.4% (38/45) of the blaCTXM genes. Given that
more than 80 types of CTX-M enzymes have been identified, the presence of rare types of
CTX-M enzymes was initially speculated as the reason for false negative results. However, this
was subsequently proven to be unlikely as bi-directional sequencing of the resistance gene con-
firmed that all the false-negative samples actually harboured the same CTX-M genotypes (i.e.
blaCTX-M-14 or blaCTX-M-15) as those which were successfully detected (Table 6). Copy numbers
of the plasmid below the detection limit could be another possible cause of false negativity for
these cases, though the hypothesis has yet to be confirmed. In addition to blaCTX-M, other β-lac-
tamase genes, such as blaSHV and blaTEM, can also transfer resistance to cefotaxime. We calcu-
lated the positive and negative predictability of CTX-M detection by the BC-GN assay for
cefotaxime resistance, and the result was 100% and 87.4% respectively. This indicates that the
use of penicillin and cephalosporin is not recommended whenever the blaCTX-M gene is tested
positive by the BC-GN assay, whereas the absence of detection of the genetic markers cannot
be interpreted as an indication of susceptible isolates. The same interpretation can also be used
for carbapenem resistance determination in Gram negative bacteria using the BC-GN assay.
We determined 100% PPV for carbapenemase producing A. baumannii, however none of the
carbapenem resistant P. aeruginosa isolates were tested positive for any resistance markers by
BC-GN assay. The low NPV for carbapenem resistance in P. aeruginosa could be attributed to
the fact that resistance mechanisms other than β-lactamase production, particularly active
drug efflux pump, are more prevalent in P. aeruginosa [51, 52].
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As expected, the implementation of the Verigene test can greatly improve turnaround time
for bacterial identification, and our results supported recent studies that reported a range of
30.5 to 127 h earlier than routine identification methods [14, 16]. In particular, the Verigene
test showed the ability to differentiate the pathogenic Staphylococci and Streptococci from
common blood culture contaminants, such as CoNS and Viridans Streptococci, an average of
61 h earlier than identification based on culture-based method with the sensitivities of 97.1%-
100%. While antibiotic modification can be made based on organism identification alone for
some bacteria, the selection of most appropriate antimicrobial therapy for certain bacterial
pathogens, such as S. aureus and Enterococcus spp, greatly rely on the drug susceptibility
results. Detection ofmecA gene and vanA/vanB gene has been considered as confirmatory test
for identification of MRSA and VRE. In this study, the Verigene platform enabled identifica-
tion of MRSA and VRE to be completed 91 h to 99 h earlier as compared to conventional
method. The rapid time to identification of MRSA and VRE facilitate earlier, tailor-made,
modification to empiric therapy, which can result in better patient outcome. However, as dis-
cussed above, although the Verigene test can also be used to predict the susceptibility of Gram
negative bacteria to β-lactam drugs, negative result for resistance markers cannot exclude β-lac-
tamase-producing bacteria, and conventional drug susceptibility testing would be still required
for these isolates. Direct comparison of the processing time of the BC-GN assay and conven-
tional methods did not indicate the time saved for identification of β-lactamase-producing bac-
teria, and therefore only the time difference in bacterial identification but not drug
susceptibility determination was reported for Gram negative bacteria in this study.
There were two potential weaknesses in the design of this study. First, the sample size was
very low or even null for some specific targets, such as S. lugdunensis and resistance markers
like blaIMP, blaVIM, blaKPC and blaNDM, which are extremely rare in BSI cases within our region.
Other studies tried to demonstrate the ability of Verigene test to identify these targets by using
stimulated cultures. However, we observed that the accuracy of the Verigene test in stimulated
cultures was always better than in clinical specimens [27, 32], and therefore did not truly reflect
the performance of the assay in routine clinical practice. As we aimed to evaluate the applica-
bility of the Verigene test in our clinical laboratories, only the prospectively collected blood cul-
tures were tested although we understand that the diagnostic performance for some rarely
encountered organisms and resistance markers could not be determined in this study. Second,
since the Verigene test results were not used to modify the treatment regimen in our hospitals,
we could not determine the impact of the Verigene test on the change in hospital stay, sepsis
related mortality, cost of care, and the overall cost-effectiveness of the assay. A large-scale ran-
domized controlled trial study is recommended to further investigate how the implementation
of Verigene platform into routine workflow can benefit the patient outcome.
Compared to other studies which were subjected to a small sample size (<125 cultures) [17,
20, 32–34], a large proportion of simulated specimens (>60%) [32, 34], or a limited strain
diversity based on the single centre-based design of the study [16, 17, 19, 20], the present study
described the most comprehensive evaluation of combined use of the BC-GP and the BC-GN
assay outside U.S. to date.
It should be noted that the time saved by the Verigene test might not be as pronounced as
we described for the laboratories using MALDI-TOF MS. Recently, several studies demon-
strated that short-term incubation of positive blood cultures on solid media prior to MALDI--
TOF MS and Vitek 2 test can reduce the time to identification and the time to drug
susceptibility result to 5 hour and 11–13 hour respectively [5, 6, 53]. Compared to the conven-
tional culture-based test, these methods required shorter turnaround time without additional
cost and workload. However, the increasing trends of resistance of Gram-negative bacteria to
third-generation cephalosporins and to carbapenems as well as the high rates of methicillin-
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resistant Staphylococcus aureus across our region, further emphasize the need for rapid detec-
tion of resistance mechanism at a very early stage of infection given that the risk of death for
septic patients increased by 10% for every hour of delay in administration of effective antibiot-
ics [4]. In spite of high reagent cost, the Verigene test is a sample-to-result and fully automated
system, which can report bacterial identification and clinically important resistance determi-
nants from positive blood cultures in around 2 hour. Despite the limited clinical value of nega-
tive results for resistance marker, positive detection ofmecA, vanA and other β-lactamase
genes clearly indicate the presence of drug resistant bacteria, and modification of empirical
treatment can be done at least 10 hour ahead of the availability of rapid drug susceptibility
result by Vitek 2. To maximize the cost-effectiveness, it is suggested that the Verigene test
should be constrained to patients with high emergency, such as those with severe sepsis and
the immunocompromised patients, whereas the accelerated protocol using MALDI-TOF MS
and Vitek 2 should be integrated in routine laboratory workflow to speed up the bacterial iden-
tification and of drug susceptibility test for all positive blood cultures.
In conclusion, the overall accuracy of the Verigene test were shown to be lower than other
recent studies, which is mostly attributed to a relatively large number of polymicrobial cultures
being tested in this study. The sensitivities and specificities were generally high for most of the
common Gram positive and Gram negative organisms with the exception of Enterococcus spp.
and Klebsiella spp. Detection of genetic markers of resistance by the assay reliably identified
100%MRSA, 100% VRE, 84.4% ESBL producers and 100%MDR-Acinetobacter spp. This can
potentially facilitate earlier selection of appropriate antimicrobial therapy, improve infection
control and reduce the total cost of care for patients infected with drug resistant organisms.
Given the increasing prevalence of some nontarget organisms in BSI cases, such as K. variicola
and Aeromonas spp., inclusion of capture probes for these organisms will greatly improve the
applicability of the Verigene test in our region.
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